Vera Therapeutics (VERA) Reiterated at Overweight by Cantor Fitzgerald on Trutakna Approval
Tweet Send to a Friend
Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating and $100.00 price target on Vera Therapeutics (NASDAQ: VERA).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
